This study is in progress, not accepting new patients
A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCLA
- Dates
- study startedcompletion around
- Principal Investigator
- by Gary Schiller (ucla)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Gary Schiller (ucla)
Professor-in-Residence, Medicine. Authored (or co-authored) 151 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Kronos Bio
- ID
- NCT05028751
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- About 24 people participating
- Last Updated